Top Analysts Reveal: 3 Must-Buy Stocks for August 22, 2025

Wall Street's sharpest minds just dropped their hottest picks—and these three names keep surfacing as absolute monsters.

Breaking Down the Big Three

Forget the noise. Top-tier analysts aren’t hedging—they’re doubling down on these equities like there’s no tomorrow. Each pick carries heavyweight backing, institutional momentum, and growth trajectories that make traditional portfolios look sleepy.

Why These Stocks? Really?

No fluff, no filler—just raw performance potential. We’re talking sector dominance, aggressive expansion plays, and balance sheets so clean you could eat off them. Unless, of course, you’re still betting on bonds—good luck with that.

Timing the Trades

Markets move fast. Analyst consensus says now’s the window—before retail catches on and the big funds finish loading. Miss it, and you’re chasing. Classic finance—where FOMO isn’t just a feeling; it’s a business model.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

To find more stocks like these, take a look at TipRanks’ Analyst Top Stocks tool. It shows you a real-time list of all stocks that have been recently rated by Top-ranking Analysts. 

Here are today’s top stock picks, according to analysts. Click on any ticker to thoroughly research the stock before you decide whether to add it to your portfolio.

($INTU– Intuit is a U.S. software company that makes tax and finance tools such as TurboTax, QuickBooks, Credit Karma, and Mailchimp. Today, Jefferies analyst Brent Thill  maintained a Buy rating on the stock with a price target of $850 per share. In the last three months, all 13 Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 22.39%.

(COP) – ConocoPhillips is a U.S. energy company that explores and produces oil and natural gas worldwide. Yesterday, Roth MKM analyst LEO Mariani maintained a Buy rating on the stock with a price target of $108 per share. In the last three months, all 13 Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of about 23.12%.

(SVRA) – Savara is a U.S. biopharma company focused on rare lung diseases. Yesterday, Citizens JMP analyst Jonathan Wolleben maintained a Buy rating on the stock with a price target of $8 per share. Interestingly, five out of the six Top Analysts who recently rated the stock gave it a Buy. Taken together, their 12-month price targets imply an upside of about 96.72%. 

Who Are the Top Analysts? 

TipRanks ranks financial analysts according to the success rates of their ratings and the average return on each of their ratings. The Top Analysts have each earned a five-star ranking, thanks to the accuracy and profitability of their ratings over time. 

See real-time analyst rankings and learn more about the performance of Top Analysts on TipRanks’ Top Wall Street Analysts page.